Details of the Drug Combination

General Information of Drug Combination (ID: DC5PNL2)

Drug Combination Name

BIO-300 PMID28870136-Compound-43

Indication

Disease Entry	Status	REF
Lung adenocarcinoma	Investigative	[1]

Component Drugs

BIO-300 DMJ7NVI

PMID28870136-Compound-43 DMWGV8N

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: HOP-62

Zero Interaction Potency (ZIP) Score: 2.93

Bliss Independence Score: 3.33

Loewe Additivity Score: 1.18

LHighest Single Agent (HSA) Score: 4.6

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of BIO-300

PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Chronic myelogenous leukemia	DCPUK2R	K-562	Investigative	[5]
Clear cell renal cell carcinoma	DCPXFB6	A498	Investigative	[5]
Glioma	DC09N3D	SF-539	Investigative	[5]
High grade ovarian serous adenocarcinoma	DC30VDR	OVCAR-4	Investigative	[1]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	Clinical pipeline report, company report or official report of Humanetics.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
5	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966